Gilead to expand Irish operations, approx 40 jobs to be created in Cork

Gilead Sciences, Inc has announced plans to create 140 new jobs in Ireland, with in the region of 40 of the new positions to be located in Cork.

The company currently operates a drug product manufacturing and packing facility in Carrigtwohill that manufactures and packages 22 Gilead drug products including HIV drugs.

The company also has a financial shared services centre in Little Island, which supports Gilead affiliates in Europe, Middle East, Asia and South America and was established 11 years ago.

The company said it is currently in the process of selecting a location for its new Dublin office, where the majority of the new positions will be based.

The remaining roles will be located at Gilead’s existing Cork facilities.

The new roles will be in areas including clinical development, process development and analytical operations, legal, human resources, supply chain, information technology, facilities and engineering, and financial shared services.

The company said it has already commenced the recruitment process and expects to fill 80 of the positions over the coming 12 months, with the remainder filled by early 2022.

“Gilead has a long record of operating in Ireland and our teams here have played a critical role in ensuring that patients in Europe and other parts of the world outside of the United States have access to our medicines,” commented David Cadogan, Vice President, Manufacturing Operations and General Manager, Gilead Sciences Ireland.

“With this additional investment, we are looking forward to continuing this important work and growing our presence here in Ireland.”

The announcement has been welcomed by Cork Chamber. 

Conor Healy, CEO Cork Chamber said it was very welcome news that Gilead Sciences has announced it will create 140 new jobs.

He said the investment in its Irish operations "will be a further boost to our strong life science sector, and reinforces Ireland’s and Cork’s reputation globally as a destination for pharmaceutical industry.”